Leah Kuntz

Looking to reduce youth initiation into tobacco products, the FDA takes steps against menthol cigarettes and flavored cigars.

The FDA cleared the way to use this deep transcranial magnetic stimulation system, which may be able to help treat depression in less than 5 minutes.

A recent study evaluated the everyday efficacy of this novel treatment for major depressive disorder.

A new risperidone capsule for the treatment of schizophrenia sees positive phase 2 study results.

These states will receive funding to increase competitive integrated employment for patients with mental health conditions.

Patients with depression may have altered cortical processing of visual contrast during a major depressive episode.

While this digital therapy failed to meet its primary endpoint in a recent clinical trial, results suggest it may improve paranoia in general.

This year, the March of the Living honors of Holocaust victims and survivors, the medical community, and Dr Anthony Fauci.

CRL cites lack of substantial evidence of efficacy needed for approval.

This once-daily sprinkleable capsule may help patients aged 6 to 17 years with attention-deficit/hyperactivity disorder.

Is this treatment for bipolar disorder risking patients’ heart health?

Government funding for the drug addiction crisis is on the way.

The first study to gather unsolicited patient responses via social media finds 3 negative themes.

Service animals can help save veterans’ lives.

This investigational dual orexin receptor antagonist improved sleep overnight and daytime functioning.

As patients flock to CBD as a “natural alternative” to medications, the FDA continues to crack down on false claims.

An ex-Yale psychiatrist who skirted the Goldwater Rule is suing the university over her termination.

Misdiagnosis and late diagnosis may be preventing older patients with bipolar disorder from getting proper care.

This monoclonal antibody showed significant slowing of decline in patients with Alzheimer disease.

This social anxiety disorder treatment does not directly activate gamma-amino butyric acid (GABA-A) receptors, setting it apart from benzodiazepines.

It’s time for psychiatry to take the high road in addressing racism, especially as the psychological toll becomes more evident.

New data from the ongoing SHORELINE study may bring good news for treating MDD.

The International Psychogeriatric Association shares opportunities to improve worldwide geriatric care.

What socio-cultural events impacted the older LGBTQ+ generations, and how do they inform their current mental health status?

Should a patient at the end of her life have access to psilocybin, even if it’s illegal?

The chief medical officer of Karuna shares his thoughts exclusively with Psychiatric Times.

The FDA has approved the New Drug Application for a once-daily ADHD treatment.

If approved, this formulation of sodium oxybate will be the first once-nightly oxybate treatment for daytime sleepiness.

A new study considers how the virus might enter the brain and cause cognitive issues.

If approved by the FDA, this treatment would be the first therapy for treating depressive episodes in both bipolar I and II disorder in 2 different forms.